| The efficiency of O-(beta-hydroxyethyl)-rutosides in reducing the incidence of superficial venous insufficiency in patients with calf muscle pump dysfunction 2017 · experiment · Adults with lower-limb fractures immobilized in plaster casts | 1 g | 8 weeks | 30 |
| Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study) 1992 · Normal volunteers, 500 mg · Normal volunteers; age and sex not reported | 500 mg | 1 day | 12 |
| Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study) 1992 · Venous hypertension patients, 500 mg · Patients with venous hypertension; age and sex not reported | 500 mg | 1 day | — |
| Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study) 1992 · Diabetic microangiopathy patients, 500 mg · Patients with diabetic microangiopathy; age and sex not reported | 500 mg | 1 day | — |
| Time course of the anti-oedematous effect of different dose regimens of O-(beta-hydroxyethyl) rutosides in healthy volunteers 1993 · 500 mg/day hydroxyethylrutosides · 12 healthy young male volunteers; arm-specific age and participant count not reported | 500 mg | 10 weeks | — |
| Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability 1994 · 300 mg three times daily (FRG and Belgium) · Patients aged over 65 years with chronic venous insufficiency or varicose veins | 900 mg | 26 weeks | 55 |
| Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability 1994 · 250 mg four times daily (UK) · Patients aged over 65 years with chronic venous insufficiency or varicose veins | 1 g | 26 weeks | 19 |
| Trihydroxyethylrutosides in the treatment of hemorrhoids of pregnancy: a double-blind placebo-controlled trial 2001 · Trihydroxyethylrutosides (HR) group · Pregnant patients in the 16th–34th week with first- or second-degree hemorrhoids | 600 mg | 4 weeks | — |
| A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy 1992 · O-(beta-hydroxyethyl)rutosides group · pregnant women with first-, second-, or third-degree haemorrhoids | 1 g | 4 weeks | — |
| Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study) 1992 · Venous hypertension patients, 1000 mg · Patients with venous hypertension; age and sex not reported | 1 g | 1 day | — |
| Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study) 1992 · Diabetic microangiopathy patients, 1000 mg · Patients with diabetic microangiopathy; age and sex not reported | 1 g | 1 day | — |
| Time course of the anti-oedematous effect of O-(beta-hydroxyethyl)-rutosides in healthy volunteers 1991 · HR · healthy volunteers | 1 g | 3 weeks | — |
| Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency 1993 · oxerutins · Post-menopausal women with grade II chronic venous insufficiency | 900 mg | 12 weeks | — |
| Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency 1993 · troxerutin · Post-menopausal women with grade II chronic venous insufficiency | 900 mg | 12 weeks | — |
| Time course of the anti-oedematous effect of different dose regimens of O-(beta-hydroxyethyl) rutosides in healthy volunteers 1993 · 1000 mg/day hydroxyethylrutosides · 12 healthy young male volunteers; arm-specific age and participant count not reported | 1 g | 10 weeks | — |
| Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings 1996 · oxerutins · female patients with grade II chronic venous insufficiency | 1 g | 12 weeks | — |
| Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency 1996 · HR (1000 mg/d) · Postmenopausal women with stage II chronic venous insufficiency | 1 g | 16 weeks | — |
| The effects of rutin flavonoid supplement on glycemic status, lipid profile, atherogenic index of plasma, brain-derived neurotrophic factor (BDNF), some serum inflammatory, and oxidative stress factors in patients with type 2 diabetes mellitus: A double-blind, placebo-controlled trial 2023 · supplement · Patients with type 2 diabetes mellitus; age and sex not stated | 500 mg | 90 days | 25 |
| The LONFLIT4-Venoruton Study: a randomized trial--prophylaxis of flight-edema in venous patients 2003 · treatment group · Adults with uncomplicated varicose veins and chronic venous disease traveling on long-haul flights | 2 g | 3 days | 80 |
| Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability 1994 · 300 mg four times daily (The Netherlands) · Patients aged over 65 years with chronic venous insufficiency or varicose veins | 1.2 g | 26 weeks | 30 |
| The LONFLIT4-VENORUTON study: a randomized trial prophylaxis of flight-edema in normal subjects 2003 · Venoruton treatment group · Normal subjects travelling in economy on long-haul flights | 2 g | 3 days | — |
| Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency 2006 · oxerutins group · Adults aged 35–75 with severe chronic venous insufficiency and ankle swelling | 2 g | 8 weeks | — |
| The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study 1994 · hydroxyethylrutosides · People with mild to moderate venous incompetence, superficial varicose veins and/or deep venous disease, and ankle oedema | 2 g | 4 weeks | — |
| The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results 2025 · food supplement (FS) · Adults aged 18–80, women and men, with metabolic syndrome; mean age 65 ± 10 years | 720 mg | 8 weeks | 19 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 157 mg | 26 weeks | 15 |
| Supplementation with Whey Protein, Omega-3 Fatty Acids and Polyphenols Combined with Electrical Muscle Stimulation Increases Muscle Strength in Elderly Adults with Limited Mobility: A Randomized Controlled Trial 2020 · WPI + BIO · Adults aged 60–90 with mobility limitations and gait speed below 1.5 m/s | 500 mg | 12 weeks | 10 |
| The reduction impact of monoglucosyl rutin on abdominal visceral fat: A randomized, placebo-controlled, double-blind, parallel-group 2020 · MR400 group · Healthy Japanese men and women with BMI ≥23; age not reported | 400 mg | 8 weeks | 20 |
| Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial 2002 · Group D · Healthy subjects | 1 g | 4 weeks | 10 |
| Eating buckwheat cookies is associated with the reduction in serum levels of myeloperoxidase and cholesterol: a double blind crossover study in day-care centre staffs 2011 · tartary buckwheat cookies · Female day-care-centre staff; age and health condition not reported | 360 mg | 2 weeks | — |
| Pharmacokinetics and bioavailability of quercetin glycosides in humans 2001 · quercetin-3-O-rutinoside (rutin) · 12 healthy volunteers | 200 mg | 1 day | 12 |
| HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial 2002 · Venoruton group · Adults with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis; mean age 41 years | 2 g | 8 weeks | 46 |
| HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study 2005 · HR group · Adults with severe chronic venous insufficiency, venous hypertension and ankle swelling | 2 g | 8 weeks | 46 |
| HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial 2002 · treatment group · Patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis; mean age 45 years | 2 g | 8 weeks | 31 |
| Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial 2002 · Group A · Patients with venous hypertension and ambulatory venous pressure > 42 mmHg | 1.5 g | 4 weeks | 30 |
| Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial 2002 · Group B · Patients with venous hypertension and ambulatory venous pressure > 42 mmHg | 3 g | 4 weeks | 30 |
| Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial 2002 · treatment group · Adults with chronic venous insufficiency and venous microangiopathy; mean age 46 years; 6 females among 20 patients | 2 g | 4 weeks | 20 |
| The reduction impact of monoglucosyl rutin on abdominal visceral fat: A randomized, placebo-controlled, double-blind, parallel-group 2020 · MR200 group · Healthy Japanese men and women with BMI ≥23; age not reported | 200 mg | 8 weeks | 20 |
| [Venous insufficiency in the pregnant woman. Rheological correction by troxerutin] 1991 · troxerutine · Pregnant women with clinical symptoms of lower-limb venous insufficiency | 4 g | 30 days | 12 |
| Eating buckwheat cookies is associated with the reduction in serum levels of myeloperoxidase and cholesterol: a double blind crossover study in day-care centre staffs 2011 · common buckwheat cookies · Female day-care-centre staff; age and health condition not reported | 16.5 mg | 2 weeks | — |
